摘要
目的探究不同剂量重组人干扰素α2b(rhIFNα2b)对毛细支气管炎患儿血清沉默信息调节因子1(SIRT1)水平的影响。方法选取2021年4月至2022年4月本院收治的毛细支气管炎患儿102例,随机分为对照组和观察组各51例。两组均接受常规基础治疗,对照组在常规治疗的基础上雾化吸入rhIFNα2b注射液每次10万IU/kg,观察组则雾化吸入rhIFNα2b注射液每次20万IU/kg,两组均治疗5 d。对比两组治疗前、5 d后临床症状评分、症状体征消失时间、肺功能指标、血气指标、SIRT1及细胞免疫指标水平的差异性,并评价治疗的安全性。结果5 d后,观察组患儿咳嗽、喘息、哮鸣音以及三凹征临床症状评分均低于对照组,差异有统计学意义(P<0.05)。观察组各临床指标消失时间以及住院时间均较对照组更短,差异有统计学意义(P<0.05)。5 d后,观察组患儿峰流速、潮气量、达峰时间比、血氧饱和度、动脉血氧分压以及SIRT1均较对照组更高,其呼吸阻力、二氧化碳分压、嗜酸性粒细胞以及嗜酸性粒细胞阳离子蛋白均较对照组更低,差异有统计学意义(P<0.05)。结论rhIFNα2b治疗小儿毛细支气管炎疗效显著且安全,且和每次10万IU/kg雾化吸入剂量相比,每次20万IU/kg雾化吸入剂量在缓解患儿临床症状与体征、改善肺功能及血气情况、调节机体免疫与SIRT1水平方面效果更佳。
Objective To investigate the effects of different doses of recombinant human interferonα2b(rhIFNα2b)on serum silent information regulator 1(SIRT1)levels in children with capillary bronchitis.Methods Totally 102 children with bronchiolitis admitted to our hospital from April 2021 to April 2022 were randomly divided into a control group and an observation group,with 51 cases in each group.Both groups received routine basic treatment;additionally,the control group received nebulized inhalation of rhIFNα2b injection at 100000 IU/(kg·dose),while the observation group received nebulized inhalation of rhIFNα2b injection at 200000 IU/(kg·dose),both being treated for 5 days.Compare the differences in clinical symptom scores,disappearance time of symptoms and signs,lung function indicators,blood gas indicators,SIRT1 and cellular immune indicators between the two groups before and 5 days after treatment,and evaluate the safety of treatment.Results After 5 days of treatment,the clinical symptom scores of cough,wheezing,wheezing rale,and triple concave syndrome in the observation group were lower than those in the control group(P<0.05).The disappearance time of various clinical indicators and hospitalization time in the observation group were shorter than those in the control group(P<0.05).After 5 days of treatment,PTEF,VT,TPTEF/TE,SaO 2,PaO 2,and SIRT1 in the observation group were higher than those in the control group,and their Rrs,PaCO 2,EOC,and ECP were lower than those in the control group(P<0.05).Conclusion The rhIFNα2b is effective and safe in the treatment of pediatric capillary bronchitis,and compared with 100000 IU/(kg·dose),200000 IU/(kg·dose)is more effective in relieving clinical symptoms and signs,improving lung function and blood gas,regulating body immunity and SIRT1 levels.
作者
秦圆圆
张文杰
王青青
QIN Yuanyuan;ZHANG Wenjie;WANG Qingqing(The First Ward of Pediatrics,Kaifeng People′s Hospital,Kaifeng 475000,China)
出处
《中国中西医结合儿科学》
2023年第6期540-544,共5页
Chinese Pediatrics of Integrated Traditional and Western Medicine
关键词
毛细支气管炎
重组人干扰素Α2B
血清沉默信息调节因子1
雾化吸入
预后
Capillary bronchitis
Recombinant human interferonα2b
Serum silencing information regulator 1
Nebulised inhalation
Prognosis
作者简介
秦圆圆(1988-),女,主治医师。研究方向:儿童呼吸系统疾病的诊治;通讯作者:秦圆圆,E-mail:yuan150100@163.com。
